Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 3Breast Neoplasms 3Neoplasm Metastasis 2von Hippel-Lindau Disease 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Thymus Neoplasms 1Sarcoma 1Recurrence 1Neuroendocrine Tumors 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Liposarcoma 1Leiomyosarcoma 1Kidney Neoplasms 1Endometrial Neoplasms 1Advanced Lung Neuroendocrine Tumor 1

Interventions

Nivolumab 19Specimen Handling 18cabozantinib 15Magnetic Resonance Spectroscopy 15pembrolizumab 14belzutifan 13Ipilimumab 11lenvatinib 8CTLA-4 Antigen 6Axitinib 6Biopsy 5Sunitinib 4tivozanib 3atezolizumab 3Surveys and Questionnaires 3Radiosurgery 3Everolimus 3relatlimab 2pazopanib 2palbociclib 2fludarabine 2avelumab 2aldesleukin 2Watchful Waiting 2Standard of Care 2Practice Guidelines as Topic 2Nephrectomy 2Immunoglobulin G 2Disulfides 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Everolimus × 30 days × Clear all
NCT07405164 2026-05-26

MK-6482-043

Merck Sharp & Dohme LLC

Phase 3 Recruiting
450 enrolled
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT01334073 2026-05-14

EVAX

University Hospital, Bordeaux

Phase 1 Completed
19 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
755 enrolled 28 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡